Acrivon Therapeutics Inc (ACRV)

$1.29 0.00 (N/A)
Market Cap 40.45M
Revenue (ttm) 0.00
Net Income (ttm) -80.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 125,700
Avg Vol 919,510
Day's Range N/A - N/A
Shares Out 31.36M
Stochastic %K 58%
Beta 1.64
Analysts Strong Sell
Price Target $12.00

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
ka1954
ka1954 Jul. 2 at 4:53 PM
$ACRV piece of crap. never holds above 1.34
1 · Reply
johnnyre111
johnnyre111 Jul. 2 at 4:25 PM
$ACRV This seems to be a day traders stock ? Pump and dump ? ?
3 · Reply
Dani_G_German
Dani_G_German Jul. 1 at 4:30 PM
$ACRV 1.20 is bottom
1 · Reply
lola269
lola269 Jun. 30 at 9:55 PM
$ACRV I'm a simple man I see this down I buy it
0 · Reply
ka1954
ka1954 Jun. 27 at 11:22 PM
$ACRV $GBIO $IPSC $XFOR why am i seeing so many stocks dumping right before close? GBIO, ACRV, IPSC
2 · Reply
dcrown
dcrown Jun. 27 at 10:35 PM
$ACRV Study Completion (Estimated) 2027-12-31
0 · Reply
Quaternity
Quaternity Jun. 27 at 8:31 PM
$ACRV well I have reached out to the company 4 times now and evidently their IR department has issues getting back to investors. Anyone else have luck?
2 · Reply
ka1954
ka1954 Jun. 27 at 7:57 PM
$ACRV piece of crap. down 7% based on what?
2 · Reply
ka1954
ka1954 Jun. 27 at 6:40 PM
$ACRV will this ever cross 1.35 ?
1 · Reply
DenysH
DenysH Jun. 27 at 4:29 PM
$ACRV I'm waiting for a bigger drop to buy more of this crap. Will I sit with the crap or will the investment pay off? That's it. Period
0 · Reply
Latest News on ACRV
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 7 weeks ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 2 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Apr 7, 2025, 4:05 PM EDT - 3 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 5:44 PM EDT - 3 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Mar 19, 2025, 8:00 AM EDT - 3 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Dec 12, 2024, 3:25 PM EST - 7 months ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 16, 2024, 4:00 PM EDT - 9 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Oct 11, 2024, 8:00 AM EDT - 9 months ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 18, 2024, 10:11 AM EDT - 10 months ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Sep 14, 2024, 3:10 AM EDT - 10 months ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 7:16 PM EDT - 1 year ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 16, 2024, 8:01 PM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

What To Buy After You Sell The Russell 2000

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Mar 5, 2024, 4:30 PM EST - 1 year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2024, 4:00 PM EST - 1 year ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 21, 2023, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 8:01 AM EST - 1 year ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 19, 2023, 4:32 PM EDT - 1 year ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 14, 2022, 10:16 PM EST - 2 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Acrivon Therapeutics sets IPO price range

Nov 3, 2022, 7:52 AM EDT - 2 years ago

Acrivon Therapeutics sets IPO price range

Acrivon Therapeutics Begins U.S. IPO Rollout

Oct 19, 2022, 11:50 AM EDT - 2 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout

ka1954
ka1954 Jul. 2 at 4:53 PM
$ACRV piece of crap. never holds above 1.34
1 · Reply
johnnyre111
johnnyre111 Jul. 2 at 4:25 PM
$ACRV This seems to be a day traders stock ? Pump and dump ? ?
3 · Reply
Dani_G_German
Dani_G_German Jul. 1 at 4:30 PM
$ACRV 1.20 is bottom
1 · Reply
lola269
lola269 Jun. 30 at 9:55 PM
$ACRV I'm a simple man I see this down I buy it
0 · Reply
ka1954
ka1954 Jun. 27 at 11:22 PM
$ACRV $GBIO $IPSC $XFOR why am i seeing so many stocks dumping right before close? GBIO, ACRV, IPSC
2 · Reply
dcrown
dcrown Jun. 27 at 10:35 PM
$ACRV Study Completion (Estimated) 2027-12-31
0 · Reply
Quaternity
Quaternity Jun. 27 at 8:31 PM
$ACRV well I have reached out to the company 4 times now and evidently their IR department has issues getting back to investors. Anyone else have luck?
2 · Reply
ka1954
ka1954 Jun. 27 at 7:57 PM
$ACRV piece of crap. down 7% based on what?
2 · Reply
ka1954
ka1954 Jun. 27 at 6:40 PM
$ACRV will this ever cross 1.35 ?
1 · Reply
DenysH
DenysH Jun. 27 at 4:29 PM
$ACRV I'm waiting for a bigger drop to buy more of this crap. Will I sit with the crap or will the investment pay off? That's it. Period
0 · Reply
JoeSpringer
JoeSpringer Jun. 27 at 2:18 PM
$ACRV -- The Next Big Biotech Breakout -- Acrivon Therapeutics https://www.youtube.com/live/Zqs0bTn8qf0?si=YMrGQKY-4pmxhiJa
0 · Reply
Quaternity
Quaternity Jun. 26 at 3:01 PM
$ACRV these guys are doing everything to collect as many shares as possible here. Target still 5.50
2 · Reply
RETAlerts
RETAlerts Jun. 25 at 8:16 PM
The bulls are starting to stir for $ACRV at 1.33, up since our initial alert. Watch for any breakouts above resistance levels for confirmation of further upside potential. (15 minute delay)
0 · Reply
Fib7867
Fib7867 Jun. 25 at 8:14 PM
#myATCHanalysis $ATCH #myACRVanalysis $ACRV #myNTCLanalysis $NTCL #FOURZ #4of28Z
0 · Reply
Dani_G_German
Dani_G_German Jun. 25 at 7:46 PM
$ACRV cmon baby
0 · Reply
lola269
lola269 Jun. 25 at 6:49 PM
$ACRV volume picked up a bit
0 · Reply
lola269
lola269 Jun. 23 at 7:27 PM
$IOVA bullish $ACRV $ATYR $AUTL $CCCC thoughts on these?
4 · Reply
lola269
lola269 Jun. 17 at 5:41 PM
$ACRV last couple of days I see a big pump In pm and then at market open the stock falls Does anyone know what is that?
2 · Reply
Quaternity
Quaternity Jun. 16 at 6:20 PM
$ACRV so technically we hld the 200 MA hourly. Ive been saying this is a pretty important indicator for a few months now. Still a move 6 weeks out unless there is something beyond a technical suprise. 5.50
0 · Reply
ka1954
ka1954 Jun. 13 at 7:41 PM
$ACRV just crazy that a stock can stay dead week after week
2 · Reply
Quaternity
Quaternity Jun. 13 at 7:33 PM
$ACRV did they say anything useful during their meeting today?
0 · Reply
lola269
lola269 Jun. 13 at 7:55 AM
$ACRV very
0 · Reply